ALLK News and Press, Allakos Inc. From 12/22/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since the rise of the omicron variant, the biotech and pharmaceutical sectors have been in the spotlight. While we’ve seen some companies with plenty to celebrate, not everyone has been so lucky. One company in parti...

Gainers: BiondVax (NASDAQ:BVXV) +96%. SeaChange (NASDAQ:SEAC) +46%. Acasti (NASDAQ:ACST) +43%. Society Pass (NASDAQ:SOPA) +30%. ALJ Regional Holdings (NASDAQ:ALJJ) +26%. Red Cat (OTCQB:RCAT) +23%. Getnet Adquirencia (NASDAQ:GET) +23%. Lottery (NASDAQ:LTRY) +20%. Bellerophon Therapeutics (NASD...

Shares of Allakos (NASDAQ: ALLK) are crashing 88% lower as of 10:17 a.m ET on Wednesday. The huge decline came after the company announced results from its phase 3 Enigma 2 and its phase 2/3 Kryptos clinical studies evaluating lirentelimab. Allakos reported that both clinical st...

Allakos (NASDAQ:ALLK) continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2 failed to achieve statistical significance. The studies met their histologic co-primary endpoints but failed to achieve symptomatic en...

Allakos (NASDAQ:ALLK) -86% after reports data from late-stage eosinophilic gastrointestinal disease studies. CalAmp (NASDAQ:CAMP) -21% on Q3 earnings release. Naked Brand Group (NASDAQ:NAKD) -14%. Adagio Therapeutics (NASDAQ:ADGI) -9%. Datasea (NASDAQ:DTSS) -9%. Creatd (NA...

REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported data from ENIG...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

Allakos (ALLK +2.1%) has initiated a Phase 2 clinical trial of subcutaneous (SC) lirentelimab in adult patients with moderate-to-severe atopic dermatitis. The company also announced plans to initiate two placebo-controlled trials of SC lirentelimab in patients with chronic spontaneous urticar...

– Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated – – Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 – – Phase 2 Asthma trial of subcutaneous lirentelimab to begin in Q4 2022 ...

Allakos (NASDAQ:ALLK): Q3 GAAP EPS of -$1.16 misses by $0.04. Cash and cash equivalents of $274.42M. Press Release For further details see: Allakos EPS misses by $0.04